Government-Owned Inventions; Availability for Licensing, 15596-15597 [2024-04441]
Download as PDF
<![CDATA[
15596
Federal Register / Vol. 89, No. 43 / Monday, March 4, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Benjamin Hurley at 240–276–5489 or
benjamin.hurley@nih.gov. Licensing
information may be obtained by
communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852: tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Vaccinia Virus Strain WR With
Deletion of Growth Factor Genes
(‘‘vSC20’’)
Description of Technology:
This technology relates to mutant
vaccinia virus expression vectors.
Researchers at NIAID have developed a
recombinant vaccinia virus in which the
growth factor genes were deleted from
both ends of the genome. The
recombinant vaccinia virus is attenuated
and can replicate efficiently in rapidly
dividing cells such as tumors.
The mutation in the recombinant
virus was confirmed through various
tests, including Southern blot analysis
and growth factor assays. The mutant
expression vectors show diminished
virus replication in non-dividing cells
and attenuation in animal models
compared to other vaccinia virus
expression vectors. They may have use
as vaccines, cancer therapies as well as
for gene delivery.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
VerDate Sep<11>2014
17:45 Mar 01, 2024
Jkt 262001
Potential Commercial Applications:
• Recombinant vaccinia virus with
deletion of growth factor genes can be
used for cancer therapeutics and
diagnostics.
Competitive Advantages:
• The recombinant vaccinia virus is
attenuated and can replicate efficiently
in rapidly dividing cells, such as
tumors.
• Applications include use in tumordirected gene therapy, given the
enhanced safety profile, tumor
selectivity, and the oncolytic effects
after systemic delivery.
Development Stage:
• Pre-Clinical.
Inventors: Bernard Moss, M.D., Ph.D.
and Sekhar Chakrabarti, Ph.D., both of
NIAID.
Publications: Buller, R M et al.
‘‘Deletion of the vaccinia virus growth
factor gene reduces virus virulence.’’
Journal of virology vol. 62,3 (1988): 866–
74. doi:10.1128/JVI.62.3.866–874.1988;
McCart, J A et al. ‘‘Systemic cancer
therapy with a tumor-selective vaccinia
virus mutant lacking thymidine kinase
and vaccinia growth factor genes.’’
Cancer research vol. 61,24 (2001): 8751–
7.
Intellectual Property: HHS Reference
No. E–028–2021. U.S. Patent
8506947B2, issued on August 13, 2013.
Licensing Contact: To license this
technology, please contact Benjamin
Hurley at 240–276–5489 or benjamin.
hurley@nih.gov and reference E–028–
2021.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. For
collaboration opportunities, please
contact Benjamin Hurley at 240–276–
5489 or benjamin.hurley@nih.gov.
Dated: February 14, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2024–04424 Filed 3–1–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
PO 00000
Notice.
Frm 00056
Fmt 4703
Sfmt 4703
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Peter Tung at 240–669–5483 or peter.
tung@nih.gov. Licensing information
may be obtained by communicating
with the Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Rockville,
MD 20852: tel. 301–496–2644. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished information related to the
invention.
Licensing information and copies of
the patent applications listed below may
be obtained by communicating with the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852 by
contacting Peter Tung at 240–669–5483
or peter.tung@nih.gov. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished patent applications related
to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
SUMMARY:
Enhanced Single-Component AMA1–
RON2 Vaccine Candidates: A
Breakthrough in Malaria Immunization
Description of Technology
This technology focuses on the
creation of single-component AMA1–
RON2 (Apical membrane antigen 1rhoptry neck protein 2) vaccine
candidates. These candidates are based
on a novel composition of matter
designed to elicit a more effective
immune response against the malaria
parasite Plasmodium falciparum. The
standout aspect of this technology is the
Structure-Based Design 1 (SBD1)
immunogen, engineered through a
structure-based design that significantly
enhances its ability to produce potent,
strain-transcending neutralizing
antibodies. This approach not only
surpasses the efficacy of traditional
AMA1–RON2 complexes and other
insertion fusion designs but also boasts
higher thermal stability, indicating
better preservation and longevity of the
vaccine. The technology’s increased
stability and efficiency in production
present an opportunity to lower vaccine
E:\FR\FM\04MRN1.SGM
04MRN1
Federal Register / Vol. 89, No. 43 / Monday, March 4, 2024 / Notices
manufacturing costs and simplify
logistics, especially in regions where
malaria is endemic. Additionally, the
adaptability of these immunogens for
integration with nanoparticle platforms
could further amplify their
immunogenicity, paving the way for
more robust and lasting protection
against malaria. This innovation can
potentially transform malaria
prevention and control, offering a more
effective, stable, and cost-efficient
solution to a disease that continues to
impact millions worldwide.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
• Stable single-component AMA1–
RON2 immunogens hold promise for
improving malaria prevention and
control efforts in endemic regions
around the world.
khammond on DSKJM1Z7X2PROD with NOTICES
Competitive Advantages
• No blood-stage malaria vaccine has
been approved. This technology offers a
competitive edge over other vaccine
candidates in development through its
easily manufactured single-component
AMA1–RON2 design that elicits a
potent broadly neutralizing response
that is better than competing candidates.
Development Stage
• The efficacy of stable singlecomponent AMA1–RON2 immunogens
has been validated in rat and rabbit
models. Following identification of the
most cost-effective platform for vaccine
production, the immunogens will be
advanced for virulent parasite challenge
studies in Aotus monkeys and towards
human trials.
Inventors: Niraj Tolia, Ph.D., Thayne
Dickey, Ph.D., Palak Patel, Ph.D., all of
NIAID.
Publications: Patel, P. N. et. al.,
Structure-based design of a strain
transcending AMA1–RON2L malaria
vaccine. Nat. Commun. 14, 5345 (2023).
Intellectual Property: HHS Reference
No. E–096–2023–0–US–01US–01; US
Provisional Application No. 63/524,522,
filed on June 30, 2023.
Licensing Contact: To license this
technology, please contact Peter Tung at
240–669–5483 or peter.tung@nih.gov,
and reference E–096–2023.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
VerDate Sep<11>2014
17:45 Mar 01, 2024
Jkt 262001
commercialize this technology. For
collaboration opportunities, please
contact Peter Tung at 240–669–5483 or
peter.tung@nih.gov.
Dated: February 27, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2024–04441 Filed 3–1–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Topics in Hepatology,
Pharmacology, and Toxicology.
Date: March 25–26, 2024.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jodie Michelle Fleming,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 812R,
Bethesda, MD 20892, (301) 867–5309,
flemingjm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–20–
117: Maximizing Investigators’ Research
Award for Early-Stage Investigators.
Date: March 25–26, 2024.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jonathan Arias, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5170,
MSC 7840, Bethesda, MD 20892, (301) 435–
2406, ariasj@csr.nih.gov.
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
15597
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Topics in Disease Control and
Applied Immunology.
Date: March 25, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David Balasundaram,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5189,
MSC 7840, Bethesda, MD 20892, 301–435–
1022, balasundaramd@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Molecular Genetics and Evolution.
Date: March 27, 2024.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Karobi Moitra, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, (301) 480–6893, karobi.
moitra@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; NIH
Research Enhancement Award (R15) in
Oncological Sciences.
Date: March 27, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Byung Min Chung, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 496–4056, justin.chung@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Cell and
Developmental AREA/REAP Review.
Date: March 27, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Robert O’Hagan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (240) 909–6378, ohaganr2@
csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Developmental Biology.
Date: March 27, 2024.
Time: 11:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
E:\FR\FM\04MRN1.SGM
04MRN1
]]>Agencies
[Federal Register Volume 89, Number 43 (Monday, March 4, 2024)]
[Notices]
[Pages 15596-15597]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-04441]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Peter Tung at 240-669-5483 or
[email protected]. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
Licensing information and copies of the patent applications listed
below may be obtained by communicating with the Technology Transfer and
Intellectual Property Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852 by
contacting Peter Tung at 240-669-5483 or [email protected]. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough
in Malaria Immunization
Description of Technology
This technology focuses on the creation of single-component AMA1-
RON2 (Apical membrane antigen 1-rhoptry neck protein 2) vaccine
candidates. These candidates are based on a novel composition of matter
designed to elicit a more effective immune response against the malaria
parasite Plasmodium falciparum. The standout aspect of this technology
is the Structure-Based Design 1 (SBD1) immunogen, engineered through a
structure-based design that significantly enhances its ability to
produce potent, strain-transcending neutralizing antibodies. This
approach not only surpasses the efficacy of traditional AMA1-RON2
complexes and other insertion fusion designs but also boasts higher
thermal stability, indicating better preservation and longevity of the
vaccine. The technology's increased stability and efficiency in
production present an opportunity to lower vaccine
[[Page 15597]]
manufacturing costs and simplify logistics, especially in regions where
malaria is endemic. Additionally, the adaptability of these immunogens
for integration with nanoparticle platforms could further amplify their
immunogenicity, paving the way for more robust and lasting protection
against malaria. This innovation can potentially transform malaria
prevention and control, offering a more effective, stable, and cost-
efficient solution to a disease that continues to impact millions
worldwide.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
Stable single-component AMA1-RON2 immunogens hold promise
for improving malaria prevention and control efforts in endemic regions
around the world.
Competitive Advantages
No blood-stage malaria vaccine has been approved. This
technology offers a competitive edge over other vaccine candidates in
development through its easily manufactured single-component AMA1-RON2
design that elicits a potent broadly neutralizing response that is
better than competing candidates.
Development Stage
The efficacy of stable single-component AMA1-RON2
immunogens has been validated in rat and rabbit models. Following
identification of the most cost-effective platform for vaccine
production, the immunogens will be advanced for virulent parasite
challenge studies in Aotus monkeys and towards human trials.
Inventors: Niraj Tolia, Ph.D., Thayne Dickey, Ph.D., Palak Patel,
Ph.D., all of NIAID.
Publications: Patel, P. N. et. al., Structure-based design of a
strain transcending AMA1-RON2L malaria vaccine. Nat. Commun. 14, 5345
(2023).
Intellectual Property: HHS Reference No. E-096-2023-0-US-01US-01;
US Provisional Application No. 63/524,522, filed on June 30, 2023.
Licensing Contact: To license this technology, please contact Peter
Tung at 240-669-5483 or [email protected], and reference E-096-2023.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Peter Tung at 240-669-5483 or
[email protected].
Dated: February 27, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-04441 Filed 3-1-24; 8:45 am]
BILLING CODE 4140-01-P
